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A hallmark of obesity is selective suppression of
hepatic insulin signaling (‘‘insulin resistance’’), but
critical gaps remain in our understanding of the
molecular mechanisms. We now report a major role
for hepatic CaMKII, a calcium-responsive kinase
that is activated in obesity. Genetic targeting of
hepatic CaMKII, its downstream mediator p38, or
the p38 substrate and stabilizer MK2 enhances insu-
lin-induced p-Akt in palmitate-treated hepatocytes
andobesemouse liver, leading tometabolic improve-
ment. The mechanism of improvement begins with
induction of ATF6 and the ATF6 target p58IPK, a
chaperone that suppresses the PERK—p-eIF2a—
ATF4 branch of the UPR. The result is a decrease in
the ATF4 target TRB3, an inhibitor of insulin-induced
p-Akt, leading to enhanced activation of Akt and
its downstream metabolic mediators. These findings
increase our understanding of the molecular mecha-
nisms linking obesity to selective insulin resistance
and suggest new therapeutic targets for type 2 dia-
betes and metabolic syndrome.
INTRODUCTION
Obesity is the leading cause of insulin resistance, metabolic syn-
drome, and type 2 diabetes (T2D), but therapeutic options are
limited due to critical gaps in our knowledge of molecular mech-
anisms linking obesity with the metabolic disturbances of insulin
resistance and T2D (Samuel and Shulman, 2012). A key factor in
T2D is an inappropriate increase in hepatic glucose production
(HGP), which results from selective hepatic insulin resistance
together with impaired suppression of glucagon signaling (Lin
and Accili, 2011). In addition to elevated HGP, selective insulin
resistance contributes to other critical maladies associated
with T2D, including cardiovascular disease, the leading causeCell Mof death in these patients (Bornfeldt and Tabas, 2011; Leavens
and Birnbaum, 2011).
We recently elucidated a pathway through which glucagon
stimulates HGP in fasting and in obesity, and in obesity this
pathway contributes to hyperglycemia (Ozcan et al., 2012;
Wang et al., 2012). The pathway is triggered downstream of
the glucagon receptor by PKA-mediated activation of the
endoplasmic reticulum (ER) calcium release channel, inositol
1,4,5-triphosphate receptor (IP3R). Channel opening, which
is also promoted by a glucagon receptor-phospholipase
C pathway that generates IP3, results in release of calcium
from ER stores, which then activates the cytoplasmic cal-
cium-sensitive kinase, calcium/calmodulin dependent-protein
kinase II (CaMKII). CaMKII then activates the MAPK p38a,
which phosphorylates FoxO1 in a manner that promotes
FoxO1 nuclear translocation. Nuclear FoxO1 induces target
genes that are rate limiting for glycogenolysis and gluconeo-
genesis, notably G6pc and Pck1. This CaMKII-FoxO1 pathway
is complemented by the activation of the calcium-sensitive
phosphatase calcineurin, which promotes CRTC2-mediated
induction of the FoxO1 transcriptional partner, PGC1a (Wang
et al., 2012). Moreover, recent studies have shown that calcium
transport back into the ER, mediated by sarcoplasmic/endo-
plasmic reticulum calcium ATPase (SERCA), is dysfunctional
in obesity (Fu et al., 2011; Park et al., 2010), which could
contribute to both the amplitude and the duration of the path-
ological calcium response. Collectively, these data point to
the importance of intracellular calcium metabolism and CaMKII
in enhanced HGP in obesity. However, a critical remaining
question in this area was whether CaMKII plays a role in
the other major pathological process in obesity and T2D,
namely selective insulin resistance.
Defective insulin signaling is a major feature of selective
hepatic insulin resistance in obesity (Brown and Goldstein,
2008; Ko¨nner and Bru¨ning, 2012). In normal physiology, insulin
stimulates insulin autophosphorylation of the insulin receptor
(IR), which promotes to Tyr-phosphorylation of insulin receptor
substrates 1 and 2 (IRS-1/2). Through a series of downstream
processes involving lipid mediators and protein kinases,
p-IRS-1/2 leads to Ser/Thr-phosphorylation and activation ofetabolism 18, 803–815, December 3, 2013 ª2013 Elsevier Inc. 803
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CaMKII Suppresses Insulin Signaling in Obese LiverAkt (also known as protein kinase B) (Saltiel and Kahn, 2001).
Akt-induced phosphorylation of a number of substrates is
critically involved in promoting the anabolic effects of insulin
on glucose and lipid metabolism. In obesity and T2D, insulin-
induced phosphorylation of Akt is defective, which disables
the pathway that normally suppresses HGP (Lin and Accili,
2011). In theory, defective Akt phosphorylation could occur at
the level of the IR, IRS1/2, signal transducers downstream of
IRS-1/2, or Akt phosphorylation itself. Studies in obese mouse
models have shown evidence for defects in each of these
steps, depending on the model used and the focus of the
investigation, and there is also evidence for defects in insulin-
induced p-Akt in humans with T2D (Brozinick et al., 2003;
Krook et al., 1998; Saad et al., 1992). Moreover, the resulting
hyperinsulinemia excessively stimulates nonresistant insulin
pathways that mediate hepatic lipid synthesis and storage
(Brown and Goldstein, 2008) and is associated with other mal-
adies associated with T2D, such as atherosclerosis (Bornfeldt
and Tabas, 2011; Leavens and Birnbaum, 2011). Because
perturbation of proximal insulin signaling is one of the earliest
hallmarks of T2D and is responsible for the most important
complications of obesity and T2D, identification of the molecu-
lar mechanisms responsible for this defect has the potential to
aid in the development of new and more specific antidiabetic
drugs.
In this report, we identify a CaMKII/p38-mediated pathway
that plays a critical role in obesity-associated insulin resistance
in the liver. This pathway is independent of the aforementioned
CaMKII/p38-FoxO1 pathway involved in HGP in obesity.We pro-
vide evidence that obesity-activated CaMKII/p38 suppresses
insulin-induced Akt phosphorylation by activating the ER stress
effector ATF4, which in turn induces the Akt inhibitor, TRB3.
Thus, an integrated, calcium-based paradigm in hepatocytes
involved in the two cardinal features of T2D, hyperglycemia
and defective insulin signaling, is beginning to emerge, providing
new potential therapeutic targets.
RESULTS
Inhibition of Liver CaMKII, p38a, orMAPKAPK2 in Obese
Mice Lowers Plasma Insulin and Improves the Response
to Glucose Challenge
We first evaluated the role of CaMKII on plasma insulin levels
and response to glucose in three models of obese mice. In the
first model, liver CaMKII in ob/obmice was inhibited through the
use of an adenoviral vector expressing K43A-CaMKII (Pfleiderer
et al., 2004), which is a kinase-inactive, dominant-negative (DN)
form that has been shown to inhibit hepatic CaMKII (Ozcan
et al., 2012). We showed previously that adeno-K43A-CaMKII
treatment of ob/ob mice, as compared with ob/ob mice treated
with adeno-LacZ control vector, lowered blood glucose (Ozcan
et al., 2012). This effect occurred in the absence of any change
in body weight (44.8 ± 1.9 g versus 43.5 ± 1.6 g), food intake
(5.3 ± 0.3 g versus 5 ± 0.2 g per mouse per day), or epididymal
fat pad mass (3.2 ± 0.2 g versus 3 ± 0.1 g). Moreover, K43A-
CaMKII-treated mice displayed a more than 2-fold reduction in
plasma insulin concentration compared with control adeno-
LacZ-treated mice (Figure 1A), consistent with an increase in
insulin sensitivity. In support of this conclusion, adeno-K43A-804 Cell Metabolism 18, 803–815, December 3, 2013 ª2013 ElsevierCaMKII-treated ob/obmice exhibited significantly lower glucose
levels during glucose and insulin tolerance tests (Figures 1B
and 1C).
In the second model, liver CaMKIIg, which is the CaMKII iso-
form in hepatocytes, was deleted in diet-induced obese (DIO)
mice by injecting DIO Camk2gfl/fl mice with adeno-associated
virus-8 encoding Cre recombinase driven by the hepatocyte-
specific thyroxin-binding globulin promoter (AAV8-TBG-Cre)
(Sun et al., 2012). This treatment successfully silenced Camk2g
in the hepatocytes (Figure 1D) without changing body weight
(44.6 ± 2.29 g versus 43 ± 0.7 g), food intake (3.13 ± 0.17 g versus
2.92 ± 0.19 g per mouse per day), or epididymal fat pad mass
(2.4 ± 0.14 g versus 2.24 ± 0.07 g). Consistent with the ob/ob
data, DIO mice that lack hepatocyte CaMKIIg had lower fasting
insulin levels (Figure 1E), lower blood glucose levels (Figure 1F),
and an improved blood glucose response to glucose challenge
(Figure 1G). Similar results were found using a third model, in
which holo-CaMKIIg KO (Camk2g/) mice were placed on the
high fat diet (see Figures S1A and S1B available online).
Consistent with an improvement in insulin resistance, target-
ing hepatocyte CaMKIIg in obese mice (AAV8-TBG-Cre) led to
a decrease in hepatic steatosis (Figure S1C); hepatocyte TG
content was also decreased in the Cre-treated mice (79.13 ±
7.21 versus 59.6 ± 7.27 mg per g liver). The decrease in hepatic
steatosis was not due to an increase in triglyceride secretion,
as the Cre-treated mice had a decrease in plasma triglyceride
levels (266.78 ± 28.08 versus 193.34 ± 13.01 mg per dl). These
combined data suggest that hepatic CaMKIIg plays a central
role in the manifestations of obesity-induced insulin resistance.
Hepatic p38 activation has been implicated in insulin
resistance in obese mice (Hemi et al., 2011), but the upstream
and downstream mechanisms remain incompletely understood.
We have previously shown that CaMKII regulates p38a MAPK
activity in hepatocytes (Ozcan et al., 2012), and so we explored
the possibility that p38 might also function as a downstream
mediator of CaMKII in the pathogenesis of insulin resistance.
To this end, the gene encoding p38a (Mapk14) was silenced
in hepatocytes by injecting DIO Mapk14fl/fl mice with AAV-
TBG-Cre, which led to more than 90% silencing of p38a protein
levels in liver (below) without affecting body weight (41 ± 2.36 g
versus 39 ± 1.04 g), food intake (2.62 ± 0.09 g versus 2.24 ±
0.06 g per mouse per day), or epididymal fat pad mass
(1.92 ± 0.15 g versus 1.83 ± 0.14 g). Compared with control
mice (AAV-TBG-LacZ), mice deficient in hepatocyte p38a had
lower fasting blood glucose (Figure 2A), lower plasma insulin
levels (Figure 2B), improved blood glucose response to glucose
challenge, and enhanced glucose disposal upon insulin stimula-
tion (Figures 2C and 2D).
MAPK-activating protein kinase 2 (MK2) is a well-character-
ized downstream effector of p38 (Freshney et al., 1994; Rouse
et al., 1994). Moreover, activated MK2 forms a tight complex
with p38a and thus reciprocally stabilizes p38a (Gaestel, 2006).
To investigate the role of MK2, ob/ob mice were injected i.v.
with adenovirus encoding MK2 with a mutation in its p38
phosphorylation site (T222A), which acts as a DN form of the
enzyme (Streicher et al., 2010). This treatment resulted in
lowering of blood glucose (Figure 2E) and plasma insulin levels
(Figure 2F) and amarked improvement in glucose tolerance (Fig-
ure 2G), without changing body weight (49.4 ± 2.01 g versusInc.
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Figure 1. Inhibition or Deletion of Liver CaMKIIg Lowers Plasma Insulin and Improves Response to Glucose and Insulin Challenge in Obese
Mice
(A) Nine-week-old ob/obmice were fasted for 6 hr, assayed for plasma insulin (‘‘pre-adeno’’), and then injected with adeno-LacZ (n = 6) or adeno-K43A-CaMKII
(n = 6). Seven days later, after a 6 hr fast, the mice were assayed again for plasma insulin (‘‘day 7’’) (*p < 0.05, **p < 0.01; mean ± SEM).
(B) Glucose tolerance tests were performed after overnight fasting (*p < 0.05, **p < 0.01; mean ± SEM). Area under the curve (AUC) is quantified in the right panel
(**p < 0.01; mean ± SEM).
(C) Insulin tolerance tests were performed after 6 hr fasting (*p < 0.05; mean ± SEM).
(D–G) LiverCaMKIIgmRNA, fasting plasma insulin, fasting blood glucose, and blood glucose after glucose challenge in DIOCamk2gfl/fl mice after treatment with
adeno-associated virus (AAV) containing either hepatocyte-specific TBG-Cre recombinase (TBG-Cre) (n = 5) or the control vector (TBG-LacZ) (n = 5) (*p < 0.05,
**p < 0.01; mean ± SEM). AUC for the glucose tolerance test is quantified in the right panel (**p < 0.01; mean ± SEM).
See also Figure S1.
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CaMKII Suppresses Insulin Signaling in Obese Liver51.4 ± 0.67 g) or food intake (5.37 ± 0.44 g versus 5.52 ± 0.23 g
per mouse per day). Thus, liver p38a and MK2, like CaMKII, play
an important role in the development of hyperglycemia and hy-
perinsulinemia in obese mice and the response of these mice
to exogenous glucose.
Deletion or Inhibition of CaMKII, p38a, or MK2 Improves
Insulin-Induced Akt Phosphorylation in Obese Mice
In view of the above data, we focused our attention on hepato-
cyte insulin signaling, where defects contribute to insulin resis-
tance in obesity (Brown and Goldstein, 2008). As a measure of
hepatic insulin signaling, we assayed pSer473-Akt in the livers
of mice injected with insulin through the portal vein. The data
show a significant increase in insulin-induced p-Akt in the livers
ofCamk2g/DIOmice compared withWT DIOmice (Figure 3A,
top two blots). Improvements in Akt phosphorylation are often
associated with increased tyrosine phosphorylation of IR and/
or IRS-1/2. However, in the case of DIO CaMKII KO mice, phos-
phorylation of neither IR (data not shown) nor IRS-1 was
increased (Figure 3A, bottom two blots). Similar results were
found in DIO Camk2gfl/fl mice injected with AAV-TBG-Cre andCell Min ob/ob mice treated with DN adeno-K43A-CaMKII: insulin-
induced phosphorylation of Akt was increased, but phosphoryla-
tion of IR and IRS-1 was not (Figures 3B and S2A). Note that
inhibition of CaMKII in chow-fed lean mice did not induce
significant changes in p-Akt levels (Figure S2B), indicating a
specific role of CaMKII in defective insulin-induced p-Akt in
obese mice.
The data in Figure 2 showed that liver-directed silencing of
either p38, which is a downstream target of CaMKII, or MK2,
which is a substrate and stabilizer of p38, improved plasma insu-
lin and response to glucose and insulin. To link these findings to
hepatic insulin signaling, we treated DIO Mapk14fl/fl mice with
AAV-TBG-Cre and then assayed insulin-induced p-Akt. As with
CaMKII silencing, there was enhanced insulin-stimulated Akt
phosphorylation without an increase in IR or IRS-1/2 phosphory-
lation (Figure 3C). Similarly, Akt activationwas increased inob/ob
mice injected with DN adeno-T222A-MK2 (Figure S2C) without
an increase in the phosphorylation of IR or IRS proteins (data
not shown). These combined data indicate that CaMKII, p38a,
and MK2 participate in defective insulin-p-Akt signaling in the
livers of obese mice at a step to distal to IRS phosphorylation.etabolism 18, 803–815, December 3, 2013 ª2013 Elsevier Inc. 805
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Figure 2. Inhibition or Deletion of p38a or MAPKAPK2 (MK2) Lowers Plasma Glucose and Insulin and Improves Response to Glucose and
Insulin Challenge in Obese Mice
(A–D) Fasting blood glucose, plasma insulin, glucose, and insulin tolerance tests in DIO Mapk14fl/fl mice after treatment with AAV-TBG-LacZ (n = 5) or AAV-
TBG-Cre (n = 5) (*p < 0.05; mean ± SEM). Area under the curve (AUC) for the glucose tolerance test is quantified in the right panel (*p < 0.05; mean ± SEM).
(E–G) Fasting blood glucose and plasma insulin; and blood glucose after glucose challenge in ob/ob mice administered 1 3 109 pfu of adeno-LacZ (n = 5) or
adeno-T222A-MK2 (n = 5) (*p < 0.05, **p < 0.01; mean ± SEM). AUC for the glucose tolerance test is quantified in the right panel (*p < 0.05; mean ± SEM).
Cell Metabolism
CaMKII Suppresses Insulin Signaling in Obese LiverInhibition of CaMKII or p38a Improves Insulin-Induced
Akt Phosphorylation Distal to IR and IRS and in a
FoxO1-Independent Manner
To further probe mechanism, we moved to a primary murine
hepatocyte (HC) model in which insulin-induced Akt phosphory-
lation is suppressed by treatment with the saturated fatty acid
palmitate (Achard and Laybutt, 2012). Using transduction with
adeno-K43A-CaMKII, we first showed that this model recapitu-
lates the improvement in insulin-induced Akt phosphorylation
observed with CaMKII inhibition in vivo (Figure 4A, top three
blots), whereas adeno-K43A-CaMKII transduction did not evoke
any significant changes under the control, BSA-treated group.
Moreover, consistent with our in vivo findings, CaMKII inhibition
did not enhance Tyr-phosphorylation of IRS-1 (Figure 4A, right
panel), IR, or IRS-2 (data not shown). Similar data were obtained
using p38a-deficient hepatocytes in terms of p-Akt (Figure 4B,
upper panel, top three blots) and p-IR and p-IRS-1 (Figure 4B,
left lower panel). Consistent with improved Akt activation, insu-
lin-stimulated phosphorylation of the downstream Akt targets,806 Cell Metabolism 18, 803–815, December 3, 2013 ª2013 ElsevierFoxO1 and GSK-3b, were also significantly improved (Figure 4B,
right lower panel, bottom four blots), and glucose output was
significantly inhibited (49.97 ± 2.76 versus 82.78 ± 4.66 nmol/
hr/mg protein). Furthermore, in order to acquire information
about the human relevance of our murine HC studies, we tested
the effect of CaMKII inhibition in metabolism-qualified human
HCs using the palmitate model. Consistent with our murine HC
data, palmitate-induced suppression of insulin-induced p-Akt
was prevented by CaMKII inhibition using adeno-K43A-CaMKII
(Figure 4C).
We next examined whether a constitutively active mutant of
CaMKII (CA-CaMKII) is sufficient to interfere with insulin action
in the absence of palmitate. This mutant possesses an amino
acid substitution, T287D, which mimics autophosphorylation at
T287 and results in autonomous activity in the absence of bound
calcium/calmodulin (Ozcan et al., 2012; Pfleiderer et al., 2004).
The data show that CA-CaMKII resulted in a decrease in
insulin-induced Akt phosphorylation without decreasing either
p-IRS-1, which was actually increased, or p-IRS-2 (Figure 4D).Inc.
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Figure 3. Deletion of CaMKII or p38a Improves Insulin-Induced Akt Phosphorylation in Obese Mice
(A) DIOCamk2g/ orWTmice were fasted for 6 hr and then injectedwith 1.5 IU/kg insulin through the portal vein. Total liver extracts were then assayed for p-Akt,
total Akt, and b-actin by immunoblot or immunoprecipitated (IP:) for IRS-1 and then assayed by immunoblot (B:) for IRS-1 or for phospho-Tyr (PY). Densitometric
quantification of the immunoblot data is shown in the graph (*p < 0.05; mean ± SEM).
(B) As in (A), except that DIO Camk2gfl/fl mice treated with AAV-TBG-LacZ or AAV-TBG-Cre were used and p-IR was also assayed by IP/B (*p < 0.05;
mean ± SEM).
(C) As in (B), except that DIO Mapk14fl/fl mice were used, and p-IRS-2 was also assayed by IP/B (*p < 0.05; mean ± SEM).
See also Figures S2 and S3.
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CaMKII Suppresses Insulin Signaling in Obese LiverThus, CaMKII is both necessary and sufficient for the palmitate-
induced insulin signaling defect in primary HCs.
We recently demonstrated that CaMKII mediates glucagon-
induced HGP through p38-induced phosphorylation of FoxO1
on non-Akt sites (Ozcan et al., 2012). In particular, phosphoryla-
tion of FoxO1 by p38 promotes nuclear localization of FoxO1 and
transcription of FoxO1 target genes involved in HGP, and inhibi-
tion of CaMKII or p38 leads to cytoplasmic localization of FoxO1
and inhibition of HGP. Because FoxO1 has been implicated in
the regulation of Akt action (Lin and Accili, 2011), we investigated
the contribution of FoxO1 nuclear exclusion in the enhancement
of insulin signaling by CaMKII deficiency. We began with a series
of experiments using nuclear FoxO1 restoration in palmitate-
treated HCs. First, a nuclear FoxO1 bioassay—induction of the
FoxO1 gene target Igfbp1—was used to verify our previous
data (Ozcan et al., 2012) showing that deletion of CaMKIIg
caused a decrease in nuclear FoxO1 activity that could be
restored by transduction with constitutively nuclear adeno-
FoxO1-ADA (Figure S3A). We then used this model to ask
whether nuclear FoxO1 restoration would abrogate the benefit
of CaMKII deletion on insulin-induced p-Akt. As before, deletionCell MofCaMKII improved insulin-inducedp-Akt, and this improvement
was not diminished by FoxO1 restoration (Figure S3B). These
data indicate the distinct nature of the two CaMKII pathways.
Wenext investigated this importantpoint in vivo.As in leanmice,
adeno-K43A-CaMKII treatment markedly diminished nuclear
FoxO1 in the livers of obese mice (Figure S3C). However, as was
the case with HCs, restoration of nuclear FoxO1 did not reverse
the benefit of CaMKII inhibition (K43A) on insulin-induced p-Akt
(Figure S3D). Thus, the improvement in insulin-induced p-Akt by
CaMKII deficiency is not due to nuclear exclusion of FoxO1.
Rather, there appear to be two separate CaMKII pathways, one
involved in CaMKII-p38-FoxO1-dependent HGP (Ozcan et al.,
2012), and the other involved in defective insulin-induced p-Akt.
Inhibition of CaMKII or p38a Improves Insulin-Induced
Akt Phosphorylation by Suppressing TRB3
In considering mechanisms of how insulin-induced p-Akt
signaling distal to IRS proteins is regulated, we tested the role
of the pseudokinase tribble 3 (TRB3), a molecule that is
increased in the livers of obese mice and humans and was
previously shown to bind to Akt and thereby prevent itsetabolism 18, 803–815, December 3, 2013 ª2013 Elsevier Inc. 807
BA
C
D
Figure 4. Inhibition of CaMKII or p38a Improves Insulin-Induced Akt Phosphorylation in Palmitate-Treated Primary Hepatocytes
(A) Primary HCs fromWTmice were transduced with adeno-LacZ or adeno-K43A-CaMKII at anmoi of 10 and then 24 hr later incubated with either BSA control or
0.2 mM palmitate for 19 hr, with the last 5 hr in serum-free media. The cells were then treated with 100 nM insulin or vehicle control for 5 min, and lysates were
probed for p-Akt, total Akt, and b-actin by immunoblot (left panel) or immunoprecipitated for IRS-1 and then assayed by immunoblot for the total level of IRS-1 or
for phospho-Tyr (PY) (right panel).
(B) HCs from Mapk14fl/fl mice were transduced with adeno-LacZ or adeno-Cre and 24 hr later incubated with palmitate and then insulin as in (A). Lysates were
probed for p-Akt, total Akt, b-actin (upper panel), p-GSK3b, total GSK3b, p-FoxO1, and total FoxO1 by immunoblot or immunoprecipitated for IR and IRS-1 and
then assayed by immunoblot for the total level of the respective proteins or for phospho-Tyr (lower panel).
(C) Primary humanHCs (metabolismqualified) were transducedwith adeno-LacZ or adeno-K43A-CaMKII at anmoi of 30 and then 36 hr later incubatedwith either
BSA control or 0.2 mM palmitate for 10 hr, with the last 5 hr in serum-free media. The cells were then treated with 100 nM insulin or vehicle control for 5 min, and
lysates were probed for p-Akt, total Akt, and b-actin by immunoblot.
(D) As in (A), except adeno-T287D-CaMKII was used and IRS-2 was also assayed.
See also Figure S3.
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CaMKII Suppresses Insulin Signaling in Obese Liverphosphorylation by insulin (Du et al., 2003). We first investigated
the effect of CaMKII and p38 deficiency on TRB3 levels in HCs.
Palmitate treatment of control HCs led to an increase in TRB3
levels, consistent with a previous report (Cunha et al., 2012).
Most importantly, CaMKII deficiency markedly decreased
TRB3 protein andmRNA under both basal and palmitate-treated
conditions (Figures 5A and S4A). To show relevance in vivo, we
tested the effect of CaMKII deficiency or inhibition on TRB3
levels in obese mice. Consistent with the HC data, TRB3 levels
were markedly suppressed in DIO Camk2g/ mice or in ob/ob
mice transduced with adeno-K43A-CaMKII (Figure 5B).
To test the importance of TRB3 in the enhancement of insulin-
induced p-Akt conferred by CaMKII deficiency, we transduced
DIO Camk2gfl/fl mice with TRB3 in order to bring TRB3 protein
to a level similar to that in WT. TRB3 overexpression abrogated
the improvement in insulin-induced p-Akt conferred by CaMKII
deficiency (Figure S4B), indicating that the suppression of808 Cell Metabolism 18, 803–815, December 3, 2013 ª2013 ElsevierTRB3 by CaMKII deficiency is causally important in the improve-
ment in insulin signaling. We then conducted a similar experi-
ment except used physiologic refeeding (16 hr fasting followed
by 4 hr of a high-fat diet feeding) instead of portal vein insulin in-
jection to activate Akt. Similar to the case with portal vein insulin
injections, TRB3 overexpression abolished the improvement
in refeeding-induced p-Akt conferred by CaMKII inhibition (Fig-
ure 5C). In line with the effect of TRB3 restoration on insulin
signaling, treatment of mice with adeno-TRB3 abrogated the
lowering of blood glucose (Figure 5D) and plasma insulin (Fig-
ure 5E) by CaMKII inhibition in DIO mice under both fasting
and refeeding conditions. Next, we sought to examine the effect
of CaMKII deletion in TRB3-inhibited HCs. RNAi mediated
knockdown of TRB3 in CaMKII-deficient HCs did not further
improve insulin-induced p-Akt (Figure S4C), consistent with the
idea that TRB3 is the downstream effector of CaMKII in the
regulation of insulin-induced p-Akt.Inc.
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Figure 5. Improvement in Insulin-Induced Akt Phosphorylation and Glucose Homeostasis by CaMKII Deficiency Are Abrogated by Restoring
TRB3
(A) HCs from Camk2gfl/fl mice were transduced with adeno-LacZ or adeno-Cre and then 24 hr later incubated with BSA or palmitate (0.2 mM) for 19 hr. Lysates
were immunoblotted for TRB3 and b-actin.
(B) TRB3 and b-actin were probed in livers from DIO WT mice, Camk2g/ mice, or Camk2gfl/fl mice treated with TBG-LacZ or TBG-Cre. Densitometric quan-
tification of the immunoblot data is shown in the graph (*p < 0.05; mean ± SEM).
(C–E) DIO Camk2gfl/fl mice were treated with TBG-Cre or TBG-LacZ, and 5 days later half of the TBG-LacZ mice received adeno-TRB3, while the other half
received adeno-LacZ control. After 4 weeks, 5 hr fasting and fasted-refed blood glucose and plasma insulin were assayed. One week later, livers were assayed
for p-Akt, total Akt, TRB3, b-actin by immunoblotting after fasting the mice for 16 hr and then refeeding for 4 hr. Differing symbols indicate p < 0.05; mean ± SEM.
See also Figure S4.
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CaMKII Suppresses Insulin Signaling in Obese LiverThe data in our previous report (Ozcan et al., 2012) and here
indicate that, in the setting of obesity, CaMKIIg deficiency lowers
HGP by suppressing p38-mediated FoxO1 nuclear localization
and improves insulin signaling by suppressing hepatic TRB3
expression, which then leads to improvement in insulin/Akt
signaling. We showed above that nuclear FoxO1 does not affect
insulin-induced p-Akt. However, an interesting question is
whether the improvement in p-Akt (new pathway here) contrib-
utes, via Akt phosphorylation sites on FoxO1 (Lin and Accili,
2011), to nuclear exclusion of FoxO1 in obese mice lacking
CaMKII or p38. To address this issue, we disabled the improve-
ment in p-Akt in CaMKII-deficient obese mice through TRB3
restoration (above). As predicted by the idea that both pathways
contribute to the exclusion of nuclear FoxO1 by CaMKII defi-Cell Mciency in the setting of obesity, TRB3 restoration in CaMKII-defi-
cient mice led to a partial increase in nuclear FoxO1 (Figure S4D).
We then reasoned that we should be able to show no effect of
TRB3 on nuclear FoxO1 if we chose a non-insulin-resistant
model; i.e., a model where TRB3 would be irrelevant in terms of
the Akt-FoxO1 pathway. For this purpose, we used non-insulin-
resistant forskolin-treated HCs (Ozcan et al., 2012). Nuclear
FoxO1 biological activity was assayed by quantifying the mRNA
levels of the FoxO1 target genes, G6pc and Pck1. In this case,
as predicted, the suppressive effect of CaMKIIg deficiency on
forskolin-induced G6Pc and Pck1 mRNA was not abrogated by
transductionwith adeno-TRB3 (FigureS4E). Thus, in the absence
of a defect in insulin signaling, TRB3 restoration does not affect
the ability of CaMKII deficiency to suppress HGP gene induction.etabolism 18, 803–815, December 3, 2013 ª2013 Elsevier Inc. 809
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Figure 6. Improvement in Insulin-Induced Akt Phosphorylation and Glucose Homeostasis by CaMKII Deficiency Are Abrogated by Restoring
ATF4
(A) HCs from Camk2gfl/fl mice were transduced with adeno-LacZ or adeno-Cre. Twenty-four hours later, cells were incubated with tunicamycin (0.5 mg/ml) or
vehicle control for 4 hr. Nuclear lysates were immunoblotted for ATF4 and nucleophosmin (Np) as a loading control.
(B) Nuclear ATF4 and nucleophosmin (Np) were probed in livers from DIO Camk2gfl/fl mice treated with TBG-Cre or TBG-LacZ or ob/obmice treated with adeno-
LacZ or adeno-K43A-CaMKII.
(C) HCs from Camk2gfl/flmice were transduced with adeno-LacZ or adeno-Cre, and then 4 hr later half of the adeno-Cre transduced cells received adeno-ATF4,
while the other half received adeno-LacZ control. After 24 hr, the cells were incubated with palmitate, and then insulin-induced p-Akt was assayed as in Figure 4.
(D) As in (C), except that Trb3 mRNA was assayed by RT-qPCR (bars with different symbols are different from each other and control, p < 0.01; mean ± SEM).
(E and F) Sixteen-week-old DIO mice were administered adeno-LacZ or adeno-K43A-CaMKII, and then 2 days later half of the adeno-K43A-CaMKII mice
received adeno-ATF4, while the other half received adeno-LacZ control. Livers were assayed for p-Akt, total Akt, b-actin, and nuclear ATF4 and nucleophosmin
(Np) by immunoblotting after insulin injection through portal vein. Five hour fasting blood glucose and plasma insulin were assayed after 3 weeks of treatment
(bars with different symbols are different from each other and from control, p < 0.05; mean ± SEM).
See also Figure S5.
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CaMKII Suppresses Insulin Signaling in Obese LiverThese data further establish the separateness of the twoCaMKII/
p38pathways, although in thesettingof insulin resistance, FoxO1
nuclear localization is promoted by both pathways.
CaMKII Deficiency Suppresses TRB3 by Decreasing ER
Stress-Induced ATF4
TRB3 expression has been reported to be increased in cancer
cells and pancreatic islets undergoing ER stress (Bromati et al.,
2011; Corcoran et al., 2005). Moreover, in HEK293 embryonic
kidney cells treated with tunicamycin, a glycosylation inhibitor
that activates the unfolded protein response (UPR), TRB3 was
shown to be a direct transcriptional target of the ER stress-induc-
ible transcription factor ATF4 (Ohoka et al., 2005). Because
hepatic ER stress is increased obesity and may act as a link be-
tween obesity and insulin resistance (Gregor et al., 2009; Ozcan810 Cell Metabolism 18, 803–815, December 3, 2013 ª2013 Elsevieret al., 2004), we reasoned that a CaMKII-ATF4-TRB3 pathway
might be upstream of defective insulin-induced p-Akt in obese
liver. We first measured ATF4 levels in WT versus CaMKIIg-defi-
cient HCs under various conditions. Exposure to tunicamycin
increased ATF4 in control HCs, but not in CaMKII-deficient HCs
(Figure 6A). Similarly, the livers of obesemice deficient in hepatic
CaMKIIg had lower ATF4 levels compared with obese WT mice
(Figure 6B), suggesting that CaMKII might be suppressing
TRB3 by first suppressing ATF4. To test this possibility and link
it to insulin-induced p-Akt, palmitate-treated CaMKIIg-deficient
HCs were transduced with adeno-ATF4 to restore the level of
this protein to the WT level. Consistent with our hypothesis,
ATF4 restoration resulted in an increase in TRB3mRNA and pro-
tein levels and abrogation of the improvement in p-Akt seen with
CaMKII deficiency (Figures 6C and 6D). To further validate theInc.
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CaMKII Suppresses Insulin Signaling in Obese Liverimportance of ATF4 suppression in the improvement of insulin
signaling by CaMKII deficiency, we restored ATF4 in adeno-
K43A-CaMKII-treated DIOmice.We observed that the beneficial
effect of CaMKIIg inhibition on insulin-induced p-Akt was abro-
gated by transduction with adeno-ATF4 (Figure 6E). Consistent
with the effect of ATF4 restoration on insulin signaling, the
blood-glucose- and plasma-insulin-lowering effect of CaMKII
inhibition in DIO mice was also abrogated by adeno-ATF4 (Fig-
ure 6F). These data support a signaling pathway in which CaMKII
promotes ATF4 expression, which in turn induces TRB3, leading
to suppression of insulin-induced p-Akt.
ATF4 is translationally upregulated when the PERK branch of
the UPR is activated (Tabas and Ron, 2011; Walter and Ron,
2011). We therefore investigated whether CaMKII deficiency
suppresses PERK activation as a mechanism for reduced
ATF-4 and TRB3 expression. When exposed to tunicamycin,
HCs lacking CaMKIIg showed amarked decrease in PERKphos-
phorylation, which is a measure of its activation, as well as
decreased expression of the ATF4 gene target CEBP/b-homolo-
gous protein (CHOP) (Figure S5A). Similar results were seen with
tunicamycin- or palmitate-treated HCs deficient in CaMKIIg or
p38a (Figures S5B and S5C). To explore a possible role of
CaMKII in the regulation of PERK branch of UPR in vivo, we
analyzed Chop mRNA levels in obese mice. Consistent with
our in vitro data, obese mice deficient in hepatic CaMKII had
lower Chop mRNA levels in liver compared with WT mice (Fig-
ure S5D). Interestingly, the IRE1a branch of the UPR, as
measured by Xbp1 mRNA splicing, was not activated either in
palmitate-treated HCs or in obese mouse liver (Figures S5E
and S5F). Thus, CaMKII deficiency selectively suppresses the
PERK branch of the UPR in the setting of obesity, leading to
decreased ATF4 and TRB3 and increased insulin-induced p-Akt.
Evidence that an ATF6-p58IPK Pathway Is Upstream of
the ATF4-TRB3-Akt Pathway
We next addressed how silencing of CaMKII might suppress the
PERK branch of the UPR. We focused on the idea that CaMKII
deficiency might increase the expression of a widely studied in-
hibitor of PERK kinase called p58IPK (Yan et al., 2002). Initial sup-
port for this idea came from the finding that p58IPK mRNA and
protein levels were increased by CaMKIIg or p38a deficiency in
ER-stressed HCs and obese mice liver (Figures 7A and S6A–
S6C). Most importantly, siRNA-mediated silencing of p58IPK
increased Trb3 and abrogated the improvement in insulin-Akt
signaling in CaMKII-deficient, palmitate-treated HCs (Figures
7B and 7C), demonstrating a casual link between the proposed
upstream role of p58IPK and the key functional endpoint of the
CaMKII pathway, insulin-induced p-Akt.
Finally, to explore howCaMKII deficiencymight increasep58IPK
in obese mice liver, we explored the role of a known inducer of
the molecule, ATF6, which has been shown to be decreased in
the livers of obese mice (Wang et al., 2009; Wu et al., 2007). This
hypothesis predicts that CaMKII deficiency would increase ATF6
levels, which was the case in obese liver and in tunicamycin-
and palmitate-treated HCs (Figures 7D, S6D, and 7F). To deter-
mine causation, we silenced Atf6 in palmitate-treated CaMKII-
deficient HCs using siRNA and found that this treatment lowered
p58ipk, increased Trb3, and reduced insulin-induced p-Akt to the
level of palmitate-treated control HCs (Figures 7E and 7F). Thus,Cell Minhibition of hepatic CaMKII improves insulin signaling in the
setting of obesity through induction of ATF6 and p58IPK, which
suppresses the PERK-ATF4-TRB3 pathway.
DISCUSSION
The epidemic of obesity and T2D demands a precise under-
standing of the molecular events that link obesity to the two car-
dinal features of T2D: hyperglycemia and insulin resistance. The
current findings, viewed together with our two recent studies
(Ozcan et al., 2012; Wang et al., 2012), present a unified scheme
in which cytosolic calcium working through CaMKII in the liver
plays a central role (Figure 7G). Cytosolic calcium in the liver is
elevated in obesity through at least two mechanisms: (1) lipid-
induced deactivation of the calcium pump SERCA (Fu et al.,
2011; Park et al., 2010) and (2) opening of the IP3R ER calcium
channel by two processes triggered by glucagon receptor acti-
vation, formation of IP3 by phospholipase C (Hansen et al.,
1998) and direct activation of the channel by PKA-mediated
phosphorylation of IP3R (Wang et al., 2012). With regard to
excessive HGP as a cause of hyperglycemia, the released cal-
cium activates both calcineurin, which promotes nuclear locali-
zation of CRTC2 (Wang et al., 2012), and CaMKII, which, through
p38, promotes nuclear localization of FoxO1 (Ozcan et al., 2012).
The current report reveals that a separate pathway in the liver,
also mediated by CaMKII-p38, disrupts insulin-induced Akt
phosphorylation, which is a key process in the pathogenesis of
insulin resistance (Brozinick et al., 2003; Cho et al., 2001; Krook
et al., 1998). From a translational viewpoint, this scheme sug-
gests that a single pathway could be therapeutically inhibited
to achieve improvement in both hyperglycemia and insulin resis-
tance in obesity and T2D.
The key downstream step through which CaMKII deficiency
improves insulin-induced p-Akt is suppression of TRB3, which
binds Akt, prevents its membrane association, and thus blocks
its phosphorylation (Du et al., 2003). TRB3 levels are increased
in the livers of obese mice and humans, and it has been pro-
posed to play a major role in hepatic insulin resistance in this
setting (Du et al., 2003; Lima et al., 2009). Notably, when TRB3
is expressed in WTmouse liver to a level similar to that observed
in obese mouse liver, insulin resistance occurs, whereas
silencing its expression in obesity improves glucose tolerance
(Du et al., 2003). Moreover, a common gain-of-function polymor-
phism in TRB3 (Q48R) that increases the ability of TRB3 to sup-
press insulin-induced p-Akt is associated with an increase in
insulin-resistant syndromes in several independent cohorts (Pru-
dente et al., 2005). TRB3 may also play a role in adipose tissue,
because TRB3 antisense oligonucleotide (ASO) treatment of
obese rats was reported to improve insulin sensitivity through
a mechanism that involved activation of PPAR-g and changes
in adipogenesis rather than an increase in p-Akt (Weismann
et al., 2011). In the case of the CaMKII pathway, the hepatic p-
Akt mechanism is clearly important, but whether changes in
PPARg and adipogenesis also occur remains to be investigated.
An important finding in our study is that CaMKII induces TRB3
through activation of the PERK-ATF4 branch of UPR, providing
a link between CaMKII and ER stress. In the context of previous
findings linking P58IPK to suppression of PERK activation
(Yan et al., 2002), our data suggest that the obesity-inducedetabolism 18, 803–815, December 3, 2013 ª2013 Elsevier Inc. 811
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Figure 7. Acute Insulin-Induced p-Akt Enhancement in Camk2g–/– Hepatocytes Is Partially Abrogated by ATF6 Inhibition
(A) p58IPK and b-actin were probed by immunoblot in livers from DIO Camk2gfl/fl mice treated with AAV-TBG-Cre or AAV-TBG-LacZ.
(B) HCs from Camk2gfl/flmice were pretreated with either scrambled RNA (first two bars) or siRNA targeting p58ipk (si-p58). After 12 hr, the cells were transduced
with adeno-LacZ or adeno-Cre. After an additional 24 hr, the cells were incubated with BSA control or palmitate (0.2 mM) for 19 hr, with the last 5 hr in serum-free
media. The cells were then assayed for Trb3mRNA by RT-qPCR (bars with different symbols are different from each other and control, p < 0.05; mean ± SEM).
(C) As in (B), except the cells were then treated with ± 100 nM insulin for 5 min, and lysates were immunoblotted for p-Akt, total Akt, b-actin, and p58IPK by
immunoblot.
(D) Nuclear ATF6 and nucleophosmin (Np) were probed by immunoblot in livers from DIO Camk2gfl/fl mice treated with AAV-TBG-Cre or AAV-TBG-LacZ.
(E) As in (B), except siRNA targeting Atf6 (siATF6) was used, and p58ipk mRNA was also assayed; the first two bars in each group received scrambled RNA (bars
with different symbols are different from each other and control, p < 0.05; mean ± SEM).
(F) HCs were prepared as in (C), except siRNA targeting Atf6 (siATF6) was used. Lysates were immunoblotted for p-Akt, total Akt, b-actin, and p58IPK by
immunoblot. In the lower blot, nuclei from a parallel set of cells treated with palmitate were probed for ATF6 and nucleophosmin (Np) by immunoblot.
(G) The data here and previously (Ozcan et al., 2012) support an integrated scheme in which CaMKII mediates two key pathways in the setting of obesity, one
contributing to defective insulin signaling and the other to excessive HGP. Thus, inhibition of liver CaMKII or its downstream agent p38 improves the two cardinal
features of T2D.
See also Figure S6.
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CaMKII Suppresses Insulin Signaling in Obese LiverCaMKII/p38 pathway activates PERK through suppression of
p58IPK. Interestingly, p58IPK-deficient mice exhibit glucosuria
and hyperglycemia through a mechanism attributed to b cell
dysfunction, suggesting the p58IPK protects b cells (Ladiges
et al., 2005). Our results now reveal another potential beneficial
effect of p58IPK in metabolism, namely improvement in hepatic
insulin signaling through suppression of CaMKII-induced ATF4
and TRB3.
We show that a key link between CaMKII/p38 deficiency and
P58IPK induction is ATF6. CaMKII-deficient obese mice have
higher nuclear ATF6 levels, and silencing ATF6 in these mice
lowers p58IPK and suppresses insulin-induced p-Akt. How inhi-
bition of the CaMKII/p38 pathway leads to increased ATF6812 Cell Metabolism 18, 803–815, December 3, 2013 ª2013 Elsevierexpression remains to be elucidated, but it is interesting to
consider previous studies linking CaMKII/p38 activation with
changes in gene expression (Backs et al., 2006; Raingeaud
et al., 1996). As with p58IPK induction and TRB3 suppression,
ATF6 activation may have additional and independent beneficial
effects in obesity and T2D. In particular, Montminy and col-
leagues have provided evidence that ATF6 could suppress
HGP through disruption of CREB-CRTC2 interaction (Wang
et al., 2009).
The discovery of a common pathway that independently
affects the two cardinal features of T2D raises the possibility of
new therapeutic targets. To the extent that excessive glucagon
signaling is at least one mechanism that likely activates theInc.
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CaMKII Suppresses Insulin Signaling in Obese LiverCaMKII-p38-MK2 pathway in T2D, relevance to humans is sug-
gested by the ability of glucagon receptor antagonists (GRAs) to
markedly lower blood sugar in human subjects (Petersen and
Sullivan, 2001). However, there may be an advantage to target-
ing amore downstream branch of the glucagon pathway in order
to avoid the possible adverse effects of GRAs (Yang et al., 2011).
In terms of the ‘‘druggability’’ of the molecules in the pathway,
CaMKII inhibitors are in development for heart failure (Rokita
and Anderson, 2012), and MK2 inhibitors are being explored
as a more effective alternative than p38 inhibitors for inflamma-
tory diseases (Huang et al., 2012). Because all new diabetes
drugs must pass safety tests for coronary artery disease, the ap-
plications of these inhibitors to T2Dmay be particularly advanta-
geous: CaMKII inhibition in liver lowers plasma cholesterol and
triglycerides in obese mice; CaMKII inhibition in macrophages
protects the cells from ER stress-induced apoptosis, a key
step in advanced plaque progression (Timmins et al., 2009);
and MK2-deficient Ldlr/ mice are protected against athero-
sclerosis (Jagavelu et al., 2007).
EXPERIMENTAL PROCEDURES
Mouse Experiments
Camk2g/ mice were generated as described previously (Backs et al., 2010)
and crossed onto the C57BL6/J background. Camk2gfl/flmice were generated
by flanking exon 1–2with loxP sites, whichwill be described in detail elsewhere
(M. Kreuber, J.B., and E.N.O., unpublished data). Ob/ob mice were obtained
from The Jackson Laboratory. Mapk14fl/fl mice were generated as described
previously (Engel et al., 2005) and generously provided by Dr. Yibin Wang,
UCLA School of Medicine. Male mice were fed a standard chow diet or a
high-fat diet with 60% kcal from fat (Research Diets) and maintained on a
12 hr light-dark cycle. Recombinant adenovirus (0.5–3 3 109 plaque-forming
units/mice) was delivered by tail vein injection, and experiments were
commenced after 5–7 days. Fasting blood glucose was measured in mice
that were fasted for 4–6 hr, with free access to water, using a glucose meter.
Glucose tolerance tests were performed in overnight-fasted mice by assaying
blood glucose at various times after i.p. injection of glucose (0.5 g/kg for ob/ob
and 1.5 g/kg for DIO). Plasma insulin levels were measured using ultrasensitive
mouse insulin ELISA Kit (Crystal Chem). Insulin tolerance tests were performed
in 5 hr-fasted mice by assaying blood glucose at various times after i.p. injec-
tion of insulin (2 IU/kg for ob/ob and 0.75–1 IU/kg for DIO). Animal studies were
performed in accordance with the Columbia University Institutional Animal
Care and Use Committee.
Portal Vein Insulin Infusion and Protein Extraction from Tissues
Following 6 hr foodwithdrawal, mice were anesthetized, and insulin (1–2 IU/kg)
or PBS was injected into mice through the portal vein. Three minutes after in-
jection, tissueswere removed, frozen in liquid nitrogen, and kept at80C until
processing. For protein extraction, tissues were placed in a cold lysis buffer
(25 mM Tris-HCl [pH 7.4], 1 mM EGTA, 1 mM EDTA, 10 mM Na4P2O7,
10 mM NaF, 2 mM Na3VO4, 1% NP-40, 2 mM PMSF, 5 mg/ml leupeptin,
10 nM okadaic acid, and 5 mg/ml aprotinin). After homogenization on ice, the
tissue lysates were centrifuged, and the supernatant fractions were used for
immunoblot analysis.
Primary Hepatocytes
Primary mouse hepatocytes (HCs) were isolated from 8- to 12-week-old mice
as described previously (Ozcan et al., 2012). For most experiments, the HCs
were cultured in DMEM containing 10% fetal bovine serum, treated as
described in the figure legends, and then incubated for 5 hr in serum-free
DMEM. HCs were transduced with adenoviral constructs 4 hr after plating,
and experiments were conducted 12 hr after transduction. Transfections
with scrambled RNA and siRNAs targeting p58ipk and Atf6 were carried out
using Lipofectamine RNAiMAX transfection reagent (Life Technologies, Inc.)
according to the manufacturer’s instructions. Metabolism-qualified humanCell MHCs were purchased from Life Technologies and cultured according to the
manufacturer’s instructions.Statistical Analysis
All results are presented as mean ± SEM. p values were calculated using
the Student’s t test for normally distributed data and the Mann-Whitney rank
sum test for nonnormally distributed data.SUPPLEMENTAL INFORMATION
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